South Korea · Delayed Price · Currency is KRW TiumBio Statistics
Total Valuation
TiumBio has a market cap or net worth of KRW 126.31 billion. The enterprise value is 130.42 billion.
| Market Cap | 126.31B |
| Enterprise Value | 130.42B |
Important Dates
The next estimated earnings date is Friday, August 14, 2026.
| Earnings Date | Aug 14, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
TiumBio has 30.04 million shares outstanding. The number of shares has increased by 5.95% in one year.
| Current Share Class | 30.04M |
| Shares Outstanding | 30.04M |
| Shares Change (YoY) | +5.95% |
| Shares Change (QoQ) | +2.90% |
| Owned by Insiders (%) | 32.85% |
| Owned by Institutions (%) | 0.02% |
| Float | 20.03M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 9.62 |
| PB Ratio | 2.70 |
| P/TBV Ratio | 3.70 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 9.93 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 1.39, with a Debt / Equity ratio of 0.66.
| Current Ratio | 1.39 |
| Quick Ratio | 1.15 |
| Debt / Equity | 0.66 |
| Debt / EBITDA | n/a |
| Debt / FCF | -2.24 |
| Interest Coverage | -2.93 |
Financial Efficiency
Return on equity (ROE) is -31.85% and return on invested capital (ROIC) is -11.35%.
| Return on Equity (ROE) | -31.85% |
| Return on Assets (ROA) | -9.38% |
| Return on Invested Capital (ROIC) | -11.35% |
| Return on Capital Employed (ROCE) | -25.26% |
| Weighted Average Cost of Capital (WACC) | 3.58% |
| Revenue Per Employee | n/a |
| Profits Per Employee | n/a |
| Employee Count | n/a |
| Asset Turnover | 0.13 |
| Inventory Turnover | 20.09 |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -27.17% in the last 52 weeks. The beta is -0.56, so TiumBio's price volatility has been lower than the market average.
| Beta (5Y) | -0.56 |
| 52-Week Price Change | -27.17% |
| 50-Day Moving Average | 7,913.40 |
| 200-Day Moving Average | 7,136.30 |
| Relative Strength Index (RSI) | 33.50 |
| Average Volume (20 Days) | 388,450 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, TiumBio had revenue of KRW 13.13 billion and -14.87 billion in losses. Loss per share was -536.69.
| Revenue | 13.13B |
| Gross Profit | 4.98B |
| Operating Income | -15.33B |
| Pretax Income | -16.16B |
| Net Income | -14.87B |
| EBITDA | -11.74B |
| EBIT | -15.33B |
| Loss Per Share | -536.69 |
Balance Sheet
The company has 37.48 billion in cash and 30.72 billion in debt, with a net cash position of 6.76 billion or 225.14 per share.
| Cash & Cash Equivalents | 37.48B |
| Total Debt | 30.72B |
| Net Cash | 6.76B |
| Net Cash Per Share | 225.14 |
| Equity (Book Value) | 46.82B |
| Book Value Per Share | 1,222.50 |
| Working Capital | 13.40B |
Cash Flow
In the last 12 months, operating cash flow was -13.27 billion and capital expenditures -422.35 million, giving a free cash flow of -13.69 billion.
| Operating Cash Flow | -13.27B |
| Capital Expenditures | -422.35M |
| Depreciation & Amortization | 3.59B |
| Net Borrowing | -4.81B |
| Free Cash Flow | -13.69B |
| FCF Per Share | -455.85 |
Margins
Gross margin is 37.91%, with operating and profit margins of -116.75% and -113.25%.
| Gross Margin | 37.91% |
| Operating Margin | -116.75% |
| Pretax Margin | -123.04% |
| Profit Margin | -113.25% |
| EBITDA Margin | -89.38% |
| EBIT Margin | -116.75% |
| FCF Margin | n/a |
Dividends & Yields
TiumBio does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -5.95% |
| Shareholder Yield | -5.95% |
| Earnings Yield | -11.77% |
| FCF Yield | -10.84% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
TiumBio has an Altman Z-Score of 1.23 and a Piotroski F-Score of 4. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 1.23 |
| Piotroski F-Score | 4 |